Shows
Tomorrow's CureThe Future of Cancer Care is HomeFor many cancer patients, treatment can be an isolating and overwhelming journey; marked by fear, fatigue, and the constant burden of travel. But what if chemotherapy could be delivered at home? In this episode, our host Cathy Wurzer explores the growing movement to bring cancer care into the comfort of patients’ homes with Dr. Roxana Dronca, Hematologist & Oncologist at Mayo Clinic and Dr. Arif Kamal, Chief Patient Officer at American Cancer Society. Could this shift not only ease the experience but also improve outcomes? Join us as we examine how innovation is transforming the future of cancer treatment....2025-07-2332 min
MedCity PivotConvenient Cancer Care with Dr. Roxana Dronca and Dr. Jeremy JonesI interviewed Dr. Roxana Dronca and Dr. Jeremy Jones who are both oncologists and are leads of Mayo Clinic's Cancer Care Beyond Walls program. Dr. Dronca had the idea of trying to find a way to deliver care of cancer patients in their home and Dr. Jones is responsible for bringing this model to other sites and even partner hospitals. Episode Resources Connect with Arundhati Parmar aparmar@medcitynews.com https://twitter.com/aparmarbb?lang=en https://medcitynews.com/ Review, Subscribe and Share ...2025-06-2730 min
OncLive® On AirFDA Approval Insights: Subcutaneous Nivolumab for Advanced Solid Tumors: With Roxana S. Dronca, MDIn today’s episode, supported by Bristol Myers Squibb, we had the pleasure of speaking with Roxana S. Dronca, MD, about the FDA approval of subcutaneous nivolumab and hyaluronidase-nvhy (Opdivo Qvantig; subcutaneous nivolumab) for advanced or metastatic solid tumors. Dr Dronca is a professor of oncology, a consultant in the Division of Hematology/Oncology in the Department of Internal Medicine, and director of the Mayo Clinic Comprehensive Cancer Center in Jacksonville, Florida.
On December 27, 2024, the FDA approved subcutaneous nivolumab across approved adult, solid tumor nivolumab indications, including as monotherapy, monotherapy maintenance after completion of nivolumab in combination with ip...2025-01-2010 min